Absorption Systems Acquires TGA Sciences, Inc., Based in Medford, MA

Absorption Systems Acquires TGA Sciences, Inc., Based in Medford, MA

Contract R&D laboratory near Cambridge reinforces Absorption Systems’ commitment to small molecules and biologics development in addition to its expertise with gene and cell therapy product testing

EXTON, Pa., Nov. 13, 2017 /PRNewswire/ — Absorption Systems, a global leader in developing GLP and GMP-compliant in vitro cell-based as well as in vivo animal models for clients in the pharmaceutical and gene/cell therapy space, announces the acquisition of TGA Sciences, Inc., a contract R&D laboratory located in Medford, MA, just outside the pharma/biotech hub of Cambridge. TGA Sciences, Inc. will become TGA Bioservices LLC, a subsidiary of Absorption Systems.

The acquisition achieves two important goals for Absorption Systems’ growth strategy. The first is expanding Absorption Systems’ expertise in research and GxP assay development services. The second strategic goal is to position Absorption Systems closer to customers in the expanding Boston/Cambridge biotech hub.
Michael Settles, who founded TGA Sciences, Inc., will continue to lead TGA BioServices as VP of Corporate Development . TGA Sciences, Inc. has emerged as a leader in the development, validation, and performance of R&D as well as regulated GLP/cGMP assays to support the development and approval of a broad range of small molecule and biological therapeutics. TGA BioServices has over 15,000 square feet of laboratory space, with analytical, R&D, bioassay, and immunochemistry labs as well as an animal facility that is AAALAC-accredited, USDA-registered, and OLAW-certified.

Patrick Dentinger, President and CEO of Absorption Systems, commented that “This deal is a natural fit for both companies, as our areas of combined expertise offer a more comprehensive service package to our expanding client base. The newly created subsidiary TGA BioServices is strategically positioned in Boston to respond to both the emerging cell and gene therapy service market and the ever-expanding small molecule market.”
Michael Settles, President and CEO of TGA Sciences, Inc. said that “After more than 20 years of providing services to our mostly local clientele, I am excited to join the Absorption Systems family because of their reputation for delivering quality services. This combination of the two companies allows us to improve our infrastructure and overall services to our already long list of clients and we look forward to moving forward.”

Chris Bode, Absorption Systems

Read full article on PR Newswire >> 
Visit TGA BioServices >>